SmithKline's Engerix-B
Executive Summary
The recombinant hepatitis B vaccine has received its first regulatory approval in Belgium. SmithKline announced in late October that it had finalized its exclusive licensing agreement with the Institut Pasteur covering the Engerix-B vaccine. Developed and produced by SmithKline's Brussels-based biologicals subsidiary, SmithKline-RIT, Engerix-B has been studied in over 6,000 patients in clinical studies in 15 countries. SmithKline said that Engerix-B is "expected to be approved and marketed in many countries in Europe, Southeast Asia and Africa within the next year".
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.